Ruxolitinib Archives - DelveInsight

Ruxolitinib

Graft versus host disease
Incyte Corporation submits positive results of trials for its drug Ruxolitinib in GvHD

Incyte Corporation has recently announced the results of Novartis-sponsored Phase III clinical trials REACH2 evaluating its candidate Ruxolitinib (Jakafi) in patients suffering from steroid-refrac...


JAK Inhibitors: New Lifeline for Hair Loss Treatment

Janus Kinase (JAK) inhibitors are the ones that inhibit the functional activity of enzymes that belong to Janus Kinase family such as JAK1, JAK2, JAK3 and TYK2 by interfering in the JAK-S...


Editor's Pick
An in-depth Assessment of the Top Drugs Launched by Leading Global Companies ...

Progress is driven by innovation. When it comes to developing novel medications and the...

Changing Dynamics of HIV-1 Treatment Market

The HIV-1 treatment market for naïve and experienced patients is evolving consistently....

Which Countries Top the Chart in Global Pharmaceutical Market?

The Pharmaceuticals segment of the Healthcare Industry has a significant market across ...

von Willebrand disease (VWD) – Misdiagnosis Still Prevalent!

Von Willebrand disease is a type of blood disorder that causes the blood to clot improp...

Analyzing the Key Companies and the Emerging Gene Therapy in the Dermatology ...

Advances in genetics research have sparked a surge in interest in gene therapy in derma...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.